Phylogica is a life sciences platform technology company focussing on delivering biologic drugs intracellularly with our proprietary library and cell penetrating peptides.

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously ‘undruggable’ targets across a range of disease types. Phylogica’s platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company’s lead asset program has identified a phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and Genetech.

Media Releases

  • Jul 2018   03:41 PM
    Phylogica (ASX:PYC) is the owner of a peptide library containing the extraordinary richness and diversity of nature. We are using these libraries to develop a drug delivery platform capable of reachin...read more
  • Jul 2018   03:15 PM
    Notice of change of interests of substantial holder  For further information please download PDF attached:
  • Jul 2018   12:06 PM
    Phylogica (ASX:PYC) is the owner of a peptide library containing the extraordinary richness and diversity of nature and is using these libraries to develop a delivery platform capable of reaching the ...read more
  • Jul 2018   12:00 PM
    Phylogica Limited (Phylogica or the Company) is pleased to advise that the terms of Dr Rohan Hockings engagement as Chief Executive Officer (CEO) have been finalised. The announcement of Dr Hocking...read more
  • May 2018   12:21 PM
    Phylogica Limited (ASX:PYC) Investor Presentation - May 2018 To view the presentation please download PDF attached:
  • May 2018   04:05 PM
    Phylogica Limited (ASX:PYC) (Phylogica or the Company), submits the following Appendix 3B in relation to the cancellation of unlisted options. For further information please download PDF attached...read more
  • May 2018   04:05 PM
    Phylogica Limited (ASX:PYC) (Phylogica or the Company), submits an amended Trading Policy pursuant to Listing Rule 12.10. To view Policy please download PDF attached:
  • May 2018   03:16 PM
    Phylogica Limited (ASX:PYC) (Phylogica or the Company), submits the following Appendix in relation to a Final Directors interest: Appendix 3Z – Final Director’s Interest Notice – ...read more
  • May 2018   12:09 PM
    PERTH, Australia, 30 April 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), invites shareholders and other interested parties to join a conference call next Monday May 7, accompanying Phy...read more
  • Apr 2018   03:20 PM
    PERTH, Australia, 30 April 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to update shareholders on pr...read more

Latest Company News


Videos

Sep 2017 04:10 PM
Phylogica (ASX:PYC) talks impr..
19 Sep 2017 - Phylogica Limited (ASX:PYC) CEO Stephanie Unwin discusses the company’s drug delivery platform technology and opportunity to deliver therapeutics to previously undruggable targets within cells.

Contact Information